Form 4: Cadrenal Therapeutics CEO Acquires 65,000 Stock Options
Ownership Change Form
Cadrenal Therapeutics CEO and Chairman, Quang X. Pham, was granted 65,000 stock options on January 23, 2025.
Summary
- Quang X. Pham, CEO and Chairman of Cadrenal Therapeutics, Inc., was granted 65,000 stock options on January 23, 2025.
- These options have an exercise price equal to 110% of the fair market value of the company's common stock on the grant date.
- The options vest 1/4 on February 1, 2026, and then pro rata monthly over the following three years, contingent on continued service to the company.
- The options expire on January 22, 2030.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. The vesting schedule and exercise price are also typical, indicating a well-structured incentive plan.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- If the CEO leaves the company before the options fully vest, he may forfeit some or all of the options.
Future Outlook
The vesting of the options is contingent on the CEO's continued service to the company.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholders.
Comparison to Industry Standards
- The vesting schedule of 1/4 on the first vesting date and then pro rata monthly over three years is a fairly standard vesting schedule for stock options in the biotech industry.
- The exercise price of 110% of the fair market value is also a common practice to ensure the options are not immediately in the money and require future stock price appreciation to be valuable.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/23/2025 | Date of the stock option grant. |
| 02/01/2026 | Date when the first 1/4 of the stock options vest. |
| 01/22/2030 | Expiration date of the stock options. |
Keywords
stock options, Cadrenal Therapeutics, CEO, Quang X. Pham, executive compensation, equity, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.